NEWSPAPER PUBLICATION OF AUDITED RESULTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Limited has submitted to BSE the newspaper cuttings of its audited financial results for the quarter and year ended 31 March 2025, published in Free Press (English) and Choutha Sansar (Hindi) on 31 May 2025, as required under SEBI LODR Regulation 47. For FY25, total revenue from operations fell to Rs. 2,255.48 lakhs from Rs. 2,712.48 lakhs in FY24, while net profit after tax declined to Rs. 57.89 lakhs from Rs. 76.86 lakhs. Basic EPS dropped to Rs. 1.14 from Rs. 1.52. The Board has deferred the declaration of dividend until further notice. During the year, the company also converted warrants into equity shares (90,391 warrants in October 2024 and 7,200 warrants in March 2025), increasing the share count.
The filing itself is a routine compliance disclosure, but the underlying results show a YoY decline in both revenue and profitability, and shareholders should note that no dividend has been declared. The warrant conversions have led to equity dilution, which retail investors should factor in when assessing per-share metrics.